



**Figure 1. Randomized, placebo controlled, cross-over trial design.** Patients were screened for eligibility. Those meeting entry criteria were randomized to a sequence: pioglitazone then placebo or placebo then pioglitazone. Patients were assessed every four weeks. Treatment phases were separated by a four week wash out period.